Q-omics provides the consensus-scored UNC5C profile across patient tissues and cancer cell-line models. UNC5C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UNC5C is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, UNC5C RNA expression shows 19,297 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, COAD, and LSCC as cancer lineages where UNC5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC5C survival associations across molecular data types. UNC5C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC5C RNA expression–survival associations across cancer types. High UNC5C expression shows unfavorable associations in BLCA, KIRP, UVM, OV and LGG, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for UNC5C RNA expression.
This table summarizes UNC5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UNC5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC5C shows lower tumor expression in COAD, BLCA, KIRP, KICH, READ and LUSC. The COAD box plot shows higher UNC5C RNA expression in normal versus tumor tissue (log2 FC = −1.904, t-test p < 0.001).
This table shows molecular features associated with UNC5C in patient tissues and cancer cell lines. In patient samples, UNC5C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
